US states drop Medicaid coverage of GLP-1 weight-loss drugs as demand rises
Experts say any short-term financial benefit will be outweighed by long-term health costs related to obesityFaced with high demand for GLP-1 drugs, some American cities and states that previously covered the cost of the weight-loss medication for low-income residents and…
By · April 14, 2026 · 1 min read
This article was originally published by
The Guardian World
and is republished here under license.
Experts say any short-term financial benefit will be outweighed by long-term health costs related to obesity
Faced with high demand for GLP-1 drugs, some American cities and states that previously covered the cost of the weight-loss medication for low-income residents and public employees have now started to restrict or eliminate coverage.
The pullback stems from the dramatic increase in public spending on drugs such as Ozempic and Wegovy in recent years.
Leave a Reply